Tigecycline is an intravenous antibiotic drug used to treat infections caused by a variety of gram-positive and gram-negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae. Tigecycline first clinically-available drug in the class of glycylcyclines antibiotics. Glycylcyclines are derived from tetracycline which are analogues are specifically designed to overcome tetracycline resistance mediated by acquired efflux pumps and/or ribosomal protection. In bacterial protein synthesis, transcription and translation occur in the cytoplasm. Tigecycline targets protein translation. Translation occurs using the bacterial 70S ribosome composed of a 50S and a 30S subunit. The ribosome has 3 binding sites, A (acceptor site), P (peptidyl site) and E (exit site). The charged tRNA with an amino acid attached (amino-acyl tRNA) binds to the A site. The P site binds to the tRNA holding the growing polypeptide chain and the E site binds to the uncharged tRNA.

Tigecycline Anti-bacterial Pathway References